Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

al products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(r) and Neurontin(r), the effects of competition on our innovative products, especially Copaxone(r) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they a
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... N.J., April 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... presented at the European League Against Rheumatism (EULAR) 2011 Annual ... 28 in London, United Kingdom, and will feature the abstracts ... The first scheduled oral presentation and the poster session will ...
... April 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ... Healthcare Conference being held May 2 to 4, 2011 at ... America Merrill Lynch Healthcare Conference being held May 10 to ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3
(Date:9/19/2014)... 19, 2014 Ticket Down has ... for her 2015 “Honeymoon” Tour. This popular ticket reseller ... savings at the checkout. , Ariana Grande 2015 Honeymoon Tour ... Center) , Feb. 28, 2015: Milwaukee, WI (BMO Harris Bradley ... Center) , March 03, 2015: Chicago, IL (Allstate Arena) , ...
(Date:9/19/2014)... 19, 2014 Singulair, developed by Merck, ... of leukotriene D4 (LTD4). LTD4 belongs to the family ... of cells, including mast cells and eosinophils, and which ... have determined that there are higher concentrations of Cys-LTs ... non-asthmatic individuals. The production of CysLTs is increased in ...
(Date:9/19/2014)... do not receive any palliative care, reveals new research ... 2014 Congress in Madrid, Spain, 26-30 September. The findings ... as 15 new oncology centres in Europe, Canada, South ... of ,ESMO Designated Centre of Integrated Oncology and Palliative ... consultant at the Institute of Oncology Bucharest, Romania, member ...
(Date:9/19/2014)... graphene has been used to detect molecules that indicate ... biosensor has been shown to be more than five ... and was able to provide results in a matter ... point-of-care diagnostic tool for patients. , The biosensor has ... 2D Materials . , To develop a viable ...
(Date:9/19/2014)... University researchers say a simple test that combines ... risk for developing Alzheimer,s disease in a person, ... of dementia., Faculty of Health Professor Lauren Sergio ... study asked the participants to complete four increasingly ... laptop computers. The test aimed at detecting the ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2
... Year, LIVINGSTON, N.J., Dec. 7 MM2 ... its wholly-owned subsidiary,Genotec Nutritionals, Inc., a New York ... distribution of its branded products and,through custom formulations ... strategic venture to manufacture sofgel capsules in Zhongsan,City, ...
... heart disease, ... Gary Stanton., MELBOURNE, Fla., Dec. 7 Heart Savior, (http://www.heartsavior.com ... one Natural product. Lowering unhealthy cholesterol levels is a good,start, but ... in the arteries and the heart muscle itself. The formulators of,Heart ...
... Conn., Dec. 7 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ... (PNH), as well as to Soliris(R),(eculizumab), a treatment for ... Society of Hematology Meeting, December 8 - 11 in ... a poster session on red,cell regulation and disorders of ...
... Dec. 6 Inverness Medical,Innovations, Inc. (Amex: ... rapid,diagnostic products for the consumer and professional markets, ... RBC Capital Markets Healthcare,Conference being held December 12, ... Ron Zwanziger, Chief Executive Officer, and Jon Russell, ...
... Effort is part of the ,Holidays at Mariners Inn - ... Friday, December 7, 2007 at 5:30 p.m. ,These men ... Dec. 6 Homeless men from the,Mariners Inn shelter and ... needy families this holiday season. The men will kick off,their ...
... The American Dietetic,Association welcomes and supports changes announced ... to the nation,s Special Supplemental,Nutrition Program for Women, ... the foods included in the WIC program more ... young children., "These changes are the most ...
Cached Medicine News:Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 2Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 3Health News:New Health Corp. Introduces Heart Savior(TM), the Ultimate Natural Heart Health Product 2Health News:Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting 2Health News:Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007 2Health News:Detroit Homeless Men Adopt Local Families for Christmas 2Health News:American Dietetic Association Supports USDA's New WIC Food Packages 2
Malaria Pf. Assay Range...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: